Výsledky vyhledávání - "Kors, van der Ent"

Akademický článek

Physiological predictors of cardiorespiratory fitness in children and adolescents with cystic fibrosis without ventilatory limitation

Autor: Marcella Burghard, Tim Takken, Merel M. Nap-van der Vlist, Sanne L. Nijhof, C. Kors van der Ent, Harry G.M. Heijerman, H.J. Erik Hulzebos

Publikováno v: Therapeutic Advances in Respiratory Disease, Vol 16 (2022)

Objectives: [1] To investigate the cardiorespiratory fitness (CRF) levels in children and adolescents with cystic fibrosis (CF) with no ventilatory limitation (ventilatory reserve ⩾ 15%) during exercise, and [2] to assess which physiological factor

Externí odkaz: https://doaj.org/article/3c0e6f4ef1c8407c886d1d8c5b194ab9

Zobrazit plný text záznamu

Akademický článek

Role of parents in fatigue of children with a chronic disease: a cross-sectional study

Autor: Merel M Nap-van der Vlist, Geertje W Dalmeijer, Martha A Grootenhuis, Joost F Swart, Elise M van de Putte, Sanne L Nijhof, Marjolijn Ketelaar, Martine van Grotel, Kors van der Ent, Niels Kramer

Publikováno v: BMJ Paediatrics Open, Vol 5, Iss 1 (2021)

Objective As parents majorly impact their child’s well-being, and as fatigue is a highly prevalent threat to the well-being of children with a chronic disease, we aimed to explore the association between parental factors and fatigue in children wit

Externí odkaz: https://doaj.org/article/2282fbab79f6462b90ff08d793f4ceea

Zobrazit plný text záznamu

Akademický článek

Fatigue among children with a chronic disease: a cross-sectional study

Autor: Merel M Nap-van der Vlist, Geertje W Dalmeijer, Martha A Grootenhuis, Marry M van den Heuvel-Eibrink, Joost F Swart, Elise M van de Putte, Sanne L Nijhof, Kors van der Ent

Publikováno v: BMJ Paediatrics Open, Vol 5, Iss 1 (2021)

Objective To determine: (1) which biological/lifestyle, psychological and/or social factors are associated with fatigue among children with a chronic disease and (2) how much each of these factors contributes to explaining variance in fatigue.Design

Externí odkaz: https://doaj.org/article/4e1e11e0963b4183a0a84968248a826f

Zobrazit plný text záznamu

Radiological and long‐term clinical response to elexacaftor/tezacaftor/ivacaftor in people with cystic fibrosis with advanced lung disease

Autor: Bente L. Aalbers, Firdaus A. A. Mohamed Hoesein, Regina W. Hofland, Inez Bronsveld, Marian A. Kruijswijk, Suzan Schotman, Corlien W. Slingerland, Hannah Panhuis, C. Kors van der Ent, Harry G. M. Heijerman

Publikováno v: Pediatric Pulmonology.

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_________::94d72f43563cac61194620ae09311b06
https://doi.org/10.1002/ppul.26486

Zobrazit plný text záznamu

Lumacaftor/ivacaftor in people with cystic fibrosis with an A455E–CFTR mutation

Autor: C. Kors van der Ent, Renske van der Meer, Sylvia F. Boj, Robert G.J. Vries, Harry G.M. Heijerman, Peter van Mourik, Paul K. Audhya, Jamie R Doyle, Jeffrey M. Beekman, Zheng Jason Yuan, N. Kinnman, Gitte Berkers

Publikováno v: Journal of Cystic Fibrosis. 20:761-767

Background Previous in vitro organoid data showed A455E–CFTR, a rare CFTR mutation with 4.1% prevalence in the Netherlands, responds to lumacaftor/ivacaftor (LUM/IVA). We explored LUM/IVA's clinical efficacy in people with CF and ≥1 A455E–CFTR

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::39e7cd4bc1b9aa6bdfa4cf0c9c20123f
https://doi.org/10.1016/j.jcf.2020.11.007

Zobrazit plný text záznamu

Long‐term effects of ivacaftor on nonpulmonary outcomes in individuals with cystic fibrosis, heterozygous for a S1251N mutation

Autor: Hj Erik Hulzebos, Hgm Harry Heijerman, Tim Takken, Fm Francis Hollander-Kraaijeveld, Ck Kors van der Ent, M. Burghard, S Sophie Ghijsen, Gitte Berkers, Km Karin de Winter-de Groot

Publikováno v: Pediatric Pulmonology

Objectives To describe the long-term effects of ivacaftor (Kalydeco®) in individuals with cystic fibrosis (CF) on body mass index (BMI), body composition (BC), pulmonary function (PF), resting energy expenditure (REE), and exercise capacity (EC) aft

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::eabc236942aa694fdb9ee0430dcee979
https://doi.org/10.1002/ppul.24745

Zobrazit plný text záznamu

VOCAL: An observational study of ivacaftor for people with cystic fibrosis and selected non-G551D-CFTR gating mutations

Autor: Nicholas J. Simmonds, C. Kors van der Ent, Carla Colombo, Nils Kinnman, Cynthia DeSouza, Teja Thorat, Marci L. Chew, Keval Chandarana, Carlo Castellani

Publikováno v: Journal of cystic fibrosis : official journal of the European Cystic Fibrosis Society.

VOCAL was an observational study of the effect of long-term ivacaftor on real-world clinical outcomes and healthcare resource utilization (HCRU) in people with cystic fibrosis (pwCF) in Italy, the Netherlands, and the UK.pwCF aged ≥6 years with non

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::e5ea9f0cd4c09ca0e416184af60afff6
https://pubmed.ncbi.nlm.nih.gov/35613999

Zobrazit plný text záznamu

Prediction of Real-World Long-Term Outcomes of People with CF Homozygous for the F508del Mutation Treated with CFTR Modulators

Autor: Danya Muilwijk, Marlou Bierlaagh, Peter van Mourik, Jasmijn Kraaijkamp, Renske van der Meer, Rutger van den Bor, Harry Heijerman, René Eijkemans, Jeffrey Beekman, Kors van der Ent

Publikováno v: Journal of Personalized Medicine; Volume 11; Issue 12; Pages: 1376
Journal of Personalized Medicine
Journal of Personalized Medicine, Vol 11, Iss 1376, p 1376 (2021)

The clinical response to cystic fibrosis transmembrane conductance regulator (CFTR) modulators is variable within people with cystic fibrosis (pwCF) homozygous for the F508del mutation. The prediction of clinical effect in individual patients would b

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::51272d6a1de871846dda421951b34def

Zobrazit plný text záznamu

Vyhledávací nástroje:

Upřesnit hledání